Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Aquaculture Vaccines Market by Product (Attenuated Live Vaccines, Inactivated Vaccines, Subunit Vaccines, DNA Vaccines, Recombinant Vaccines), by Route Of Administration (Oral, Injected, Immersion and Spray) and by Application (Bacterial, Parasitic, Viral): Global Opportunity Analysis and Industry Forecast, 2023-2032

A10284

Pages: NA

Charts: NA

Tables: NA

A vaccine is a substance that is intended to establish or improve the consumers’ immunity towards a disease. Vaccines have been used in humans, companion animals, and terrestrial livestock against a variety of diseases.

Disease is the biggest challenge in the aquaculture field. General management and favorable husbandry comprises of immunity, genetics, system management, nutrition, and water quality are the most important factors to enlarge the aquatic animal healthcare. The perfect vaccine should be secure enough for the fish, the person(s) vaccinating the fish, as well as for the end-user and it also protects against various pathogens and also helps protect against any disease. It also delivers enduring protection for the complete life cycle. These vaccines are manufactured in such a way that the application is easier and can be applied to various fish species simultaneously. These vaccines also need to be at an optimal cost and should be approved and registered in the FDA.

COVID-19 scenario analysis:

The coronavirus pandemic is having a huge impact on businesses and has already caused an unprecedented collapse of economic activities. The COVID-19 impact is straining the healthcare systems globally. The rapidly increasing demand for healthcare facilities and healthcare workers may leave only a few healthcare systems to fulfill the increasing demand during the pandemic situation. 

The COVID-19 pandemic cases are because of direct or indirect contact between humans. There has been no evidence or confirmation that animals can spread COVID-19 to humans. The myth animals can spread the virus to humans has increased the number of abandoned pets. Furthermore, COVID-19 has weakened the supply chain and has created a shortage of animal health products such as nutritional feed as well as vaccines globally. The animal health industry has been impacted largely as many manufacturers in the animal health industry are left with a significantly reduced workforce. Also, stringent government policies such as restrictions of import of raw materials from China are expected to hamper the animal health market.

Healthcare facilities are stocking up the animal-related health products, considering the high demand. This is expected to further create a financial strain on the market due to procurement inefficiencies and wasted speeding. Due to the pandemic situation, many hospitals and veterinary clinics are overstocking the products.

Owing to such factors, COVID 19 is expected to have a significant impact on the aquaculture vaccines market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

Improvement in the quality of vaccines by aquaculture breeders, appropriate guidelines, and restriction over the use of these vaccines laid by the nations are helping improve the selection and application of aquaculture vaccines. Moreover, the improvement of vaccines for aquaculture is growing the market positively. New and fast-growing vaccination research to cure virus and bacteria related diseases are expected to drive the market development. Manufacturers are now focusing on the transmission and development of the vaccines. Various research programs for the development of vaccines are expected to drive the market further.

On the other hand, strict policies and regulations required for the vaccines to enter the market is a challenge for the aquaculture market. Moreover, the development process of the vaccines is far more complex and time-consuming which is hampering the growth of the market.

New product launches and acquisitions to flourish the market:

On December 6th, 2018, Phibro Animal Health Corporation was acquired by KoVax Ltd. Phibro with the help of KoVax entered in the aquaculture vaccines market and it helped strengthen Phibro’s position in the fish vaccine innovations market.

On June 16th, 2016, Norwegian fish health firm PharmaQ ran a test on its live salmon rickettsial septicemia (SRS) vaccine on 20 million young Chilean fish, which was already approved.

On January 3rd, 2017, PharmaQ acquired Nordland Sett Vaks which helped them strengthen their fish vaccine portfolio.

Surge in usage in hospital applications:

There are various distributors, online stores, retail, and aqua stores who sell aquaculture vaccines. Online pharmacies are the biggest consumers among them. A large variety of vaccines have been catered for various diseases in aquatic animals which are helping in contributing to the demand. Moreover, there is considerable growth in online shopping. These factors will boost the online stores and are contributing to the market expansion.

Key benefits of the report:

  • This study presents the analytical depiction of the global Aquaculture vaccines industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Aquaculture vaccines market share.
  • The current market is quantitatively analyzed to highlight the global Aquaculture vaccines market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global Aquaculture vaccines market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Aquaculture vaccines Market research report:

  • What are the leading market players active in the Aquaculture vaccines market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Key Market Segments

  • By Product
    • Attenuated Live Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • DNA Vaccines
    • Recombinant Vaccines
  • By Route Of Administration
    • Oral
    • Injected
    • Immersion and Spray
  • By Application
    • Bacterial
    • Parasitic
    • Viral
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • PHIBRO ANIMAL HEALTH CORPORATION
  • CAVAC
  • Elanco
  • Zoetis Inc.
  • Hipra
  • Merck And Co. Inc.
  • Nisseiken Co. Ltd.
  • Nisseiken Co., Ltd.
  • Kyoto Biken Laboratories, Inc
  • KBNP
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: AQUACULTURE VACCINES MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Attenuated Live Vaccines

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Inactivated Vaccines

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Subunit Vaccines

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. DNA Vaccines

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Recombinant Vaccines

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: AQUACULTURE VACCINES MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Injected

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Immersion And Spray

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: AQUACULTURE VACCINES MARKET, BY APPLICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Application

    • 6.2. Bacterial

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Parasitic

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Viral

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: AQUACULTURE VACCINES MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product

      • 7.2.3. Market Size and Forecast, By Route Of Administration

      • 7.2.4. Market Size and Forecast, By Application

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Aquaculture Vaccines Market

        • 7.2.6.1. Market Size and Forecast, By Product
        • 7.2.6.2. Market Size and Forecast, By Route Of Administration
        • 7.2.6.3. Market Size and Forecast, By Application
      • 7.2.7. Canada Aquaculture Vaccines Market

        • 7.2.7.1. Market Size and Forecast, By Product
        • 7.2.7.2. Market Size and Forecast, By Route Of Administration
        • 7.2.7.3. Market Size and Forecast, By Application
      • 7.2.8. Mexico Aquaculture Vaccines Market

        • 7.2.8.1. Market Size and Forecast, By Product
        • 7.2.8.2. Market Size and Forecast, By Route Of Administration
        • 7.2.8.3. Market Size and Forecast, By Application
    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product

      • 7.3.3. Market Size and Forecast, By Route Of Administration

      • 7.3.4. Market Size and Forecast, By Application

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Aquaculture Vaccines Market

        • 7.3.6.1. Market Size and Forecast, By Product
        • 7.3.6.2. Market Size and Forecast, By Route Of Administration
        • 7.3.6.3. Market Size and Forecast, By Application
      • 7.3.7. Germany Aquaculture Vaccines Market

        • 7.3.7.1. Market Size and Forecast, By Product
        • 7.3.7.2. Market Size and Forecast, By Route Of Administration
        • 7.3.7.3. Market Size and Forecast, By Application
      • 7.3.8. Italy Aquaculture Vaccines Market

        • 7.3.8.1. Market Size and Forecast, By Product
        • 7.3.8.2. Market Size and Forecast, By Route Of Administration
        • 7.3.8.3. Market Size and Forecast, By Application
      • 7.3.9. Spain Aquaculture Vaccines Market

        • 7.3.9.1. Market Size and Forecast, By Product
        • 7.3.9.2. Market Size and Forecast, By Route Of Administration
        • 7.3.9.3. Market Size and Forecast, By Application
      • 7.3.10. UK Aquaculture Vaccines Market

        • 7.3.10.1. Market Size and Forecast, By Product
        • 7.3.10.2. Market Size and Forecast, By Route Of Administration
        • 7.3.10.3. Market Size and Forecast, By Application
      • 7.3.11. Russia Aquaculture Vaccines Market

        • 7.3.11.1. Market Size and Forecast, By Product
        • 7.3.11.2. Market Size and Forecast, By Route Of Administration
        • 7.3.11.3. Market Size and Forecast, By Application
      • 7.3.12. Rest Of Europe Aquaculture Vaccines Market

        • 7.3.12.1. Market Size and Forecast, By Product
        • 7.3.12.2. Market Size and Forecast, By Route Of Administration
        • 7.3.12.3. Market Size and Forecast, By Application
    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product

      • 7.4.3. Market Size and Forecast, By Route Of Administration

      • 7.4.4. Market Size and Forecast, By Application

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Aquaculture Vaccines Market

        • 7.4.6.1. Market Size and Forecast, By Product
        • 7.4.6.2. Market Size and Forecast, By Route Of Administration
        • 7.4.6.3. Market Size and Forecast, By Application
      • 7.4.7. Japan Aquaculture Vaccines Market

        • 7.4.7.1. Market Size and Forecast, By Product
        • 7.4.7.2. Market Size and Forecast, By Route Of Administration
        • 7.4.7.3. Market Size and Forecast, By Application
      • 7.4.8. India Aquaculture Vaccines Market

        • 7.4.8.1. Market Size and Forecast, By Product
        • 7.4.8.2. Market Size and Forecast, By Route Of Administration
        • 7.4.8.3. Market Size and Forecast, By Application
      • 7.4.9. South Korea Aquaculture Vaccines Market

        • 7.4.9.1. Market Size and Forecast, By Product
        • 7.4.9.2. Market Size and Forecast, By Route Of Administration
        • 7.4.9.3. Market Size and Forecast, By Application
      • 7.4.10. Australia Aquaculture Vaccines Market

        • 7.4.10.1. Market Size and Forecast, By Product
        • 7.4.10.2. Market Size and Forecast, By Route Of Administration
        • 7.4.10.3. Market Size and Forecast, By Application
      • 7.4.11. Thailand Aquaculture Vaccines Market

        • 7.4.11.1. Market Size and Forecast, By Product
        • 7.4.11.2. Market Size and Forecast, By Route Of Administration
        • 7.4.11.3. Market Size and Forecast, By Application
      • 7.4.12. Malaysia Aquaculture Vaccines Market

        • 7.4.12.1. Market Size and Forecast, By Product
        • 7.4.12.2. Market Size and Forecast, By Route Of Administration
        • 7.4.12.3. Market Size and Forecast, By Application
      • 7.4.13. Indonesia Aquaculture Vaccines Market

        • 7.4.13.1. Market Size and Forecast, By Product
        • 7.4.13.2. Market Size and Forecast, By Route Of Administration
        • 7.4.13.3. Market Size and Forecast, By Application
      • 7.4.14. Rest of Asia Pacific Aquaculture Vaccines Market

        • 7.4.14.1. Market Size and Forecast, By Product
        • 7.4.14.2. Market Size and Forecast, By Route Of Administration
        • 7.4.14.3. Market Size and Forecast, By Application
    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product

      • 7.5.3. Market Size and Forecast, By Route Of Administration

      • 7.5.4. Market Size and Forecast, By Application

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Aquaculture Vaccines Market

        • 7.5.6.1. Market Size and Forecast, By Product
        • 7.5.6.2. Market Size and Forecast, By Route Of Administration
        • 7.5.6.3. Market Size and Forecast, By Application
      • 7.5.7. South Africa Aquaculture Vaccines Market

        • 7.5.7.1. Market Size and Forecast, By Product
        • 7.5.7.2. Market Size and Forecast, By Route Of Administration
        • 7.5.7.3. Market Size and Forecast, By Application
      • 7.5.8. Saudi Arabia Aquaculture Vaccines Market

        • 7.5.8.1. Market Size and Forecast, By Product
        • 7.5.8.2. Market Size and Forecast, By Route Of Administration
        • 7.5.8.3. Market Size and Forecast, By Application
      • 7.5.9. UAE Aquaculture Vaccines Market

        • 7.5.9.1. Market Size and Forecast, By Product
        • 7.5.9.2. Market Size and Forecast, By Route Of Administration
        • 7.5.9.3. Market Size and Forecast, By Application
      • 7.5.10. Argentina Aquaculture Vaccines Market

        • 7.5.10.1. Market Size and Forecast, By Product
        • 7.5.10.2. Market Size and Forecast, By Route Of Administration
        • 7.5.10.3. Market Size and Forecast, By Application
      • 7.5.11. Rest of LAMEA Aquaculture Vaccines Market

        • 7.5.11.1. Market Size and Forecast, By Product
        • 7.5.11.2. Market Size and Forecast, By Route Of Administration
        • 7.5.11.3. Market Size and Forecast, By Application
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Zoetis Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Hipra

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Merck And Co. Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Nisseiken Co. Ltd.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Elanco

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. PHIBRO ANIMAL HEALTH CORPORATION

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. KBNP

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. CAVAC

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Kyoto Biken Laboratories, Inc

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Nisseiken Co., Ltd.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL AQUACULTURE VACCINES MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL AQUACULTURE VACCINES MARKET FOR ATTENUATED LIVE VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL AQUACULTURE VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL AQUACULTURE VACCINES MARKET FOR SUBUNIT VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL AQUACULTURE VACCINES MARKET FOR DNA VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL AQUACULTURE VACCINES MARKET FOR RECOMBINANT VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL AQUACULTURE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL AQUACULTURE VACCINES MARKET FOR ORAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL AQUACULTURE VACCINES MARKET FOR INJECTED, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL AQUACULTURE VACCINES MARKET FOR IMMERSION AND SPRAY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL AQUACULTURE VACCINES MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL AQUACULTURE VACCINES MARKET FOR BACTERIAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL AQUACULTURE VACCINES MARKET FOR PARASITIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL AQUACULTURE VACCINES MARKET FOR VIRAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL AQUACULTURE VACCINES MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA AQUACULTURE VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 20. U.S. AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 21. U.S. AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 22. U.S. AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 23. CANADA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 24. CANADA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 25. CANADA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE AQUACULTURE VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. ITALY AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 40. ITALY AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 41. ITALY AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. UK AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 46. UK AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 47. UK AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC AQUACULTURE VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 58. CHINA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 59. CHINA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 60. CHINA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. INDIA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 65. INDIA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 66. INDIA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA AQUACULTURE VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 98. UAE AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 99. UAE AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 100. UAE AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA AQUACULTURE VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA AQUACULTURE VACCINES, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA AQUACULTURE VACCINES, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 107. ZOETIS INC.: KEY EXECUTIVES
  • TABLE 108. ZOETIS INC.: COMPANY SNAPSHOT
  • TABLE 109. ZOETIS INC.: OPERATING SEGMENTS
  • TABLE 110. ZOETIS INC.: PRODUCT PORTFOLIO
  • TABLE 111. ZOETIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. HIPRA: KEY EXECUTIVES
  • TABLE 113. HIPRA: COMPANY SNAPSHOT
  • TABLE 114. HIPRA: OPERATING SEGMENTS
  • TABLE 115. HIPRA: PRODUCT PORTFOLIO
  • TABLE 116. HIPRA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. MERCK AND CO. INC.: KEY EXECUTIVES
  • TABLE 118. MERCK AND CO. INC.: COMPANY SNAPSHOT
  • TABLE 119. MERCK AND CO. INC.: OPERATING SEGMENTS
  • TABLE 120. MERCK AND CO. INC.: PRODUCT PORTFOLIO
  • TABLE 121. MERCK AND CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. NISSEIKEN CO. LTD.: KEY EXECUTIVES
  • TABLE 123. NISSEIKEN CO. LTD.: COMPANY SNAPSHOT
  • TABLE 124. NISSEIKEN CO. LTD.: OPERATING SEGMENTS
  • TABLE 125. NISSEIKEN CO. LTD.: PRODUCT PORTFOLIO
  • TABLE 126. NISSEIKEN CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. ELANCO: KEY EXECUTIVES
  • TABLE 128. ELANCO: COMPANY SNAPSHOT
  • TABLE 129. ELANCO: OPERATING SEGMENTS
  • TABLE 130. ELANCO: PRODUCT PORTFOLIO
  • TABLE 131. ELANCO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. PHIBRO ANIMAL HEALTH CORPORATION: KEY EXECUTIVES
  • TABLE 133. PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT
  • TABLE 134. PHIBRO ANIMAL HEALTH CORPORATION: OPERATING SEGMENTS
  • TABLE 135. PHIBRO ANIMAL HEALTH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 136. PHIBRO ANIMAL HEALTH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. KBNP: KEY EXECUTIVES
  • TABLE 138. KBNP: COMPANY SNAPSHOT
  • TABLE 139. KBNP: OPERATING SEGMENTS
  • TABLE 140. KBNP: PRODUCT PORTFOLIO
  • TABLE 141. KBNP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. CAVAC: KEY EXECUTIVES
  • TABLE 143. CAVAC: COMPANY SNAPSHOT
  • TABLE 144. CAVAC: OPERATING SEGMENTS
  • TABLE 145. CAVAC: PRODUCT PORTFOLIO
  • TABLE 146. CAVAC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. KYOTO BIKEN LABORATORIES, INC: KEY EXECUTIVES
  • TABLE 148. KYOTO BIKEN LABORATORIES, INC: COMPANY SNAPSHOT
  • TABLE 149. KYOTO BIKEN LABORATORIES, INC: OPERATING SEGMENTS
  • TABLE 150. KYOTO BIKEN LABORATORIES, INC: PRODUCT PORTFOLIO
  • TABLE 151. KYOTO BIKEN LABORATORIES, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. NISSEIKEN CO., LTD.: KEY EXECUTIVES
  • TABLE 153. NISSEIKEN CO., LTD.: COMPANY SNAPSHOT
  • TABLE 154. NISSEIKEN CO., LTD.: OPERATING SEGMENTS
  • TABLE 155. NISSEIKEN CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 156. NISSEIKEN CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL AQUACULTURE VACCINES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL AQUACULTURE VACCINES MARKET
  • FIGURE 3. SEGMENTATION AQUACULTURE VACCINES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN AQUACULTURE VACCINES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALAQUACULTURE VACCINES MARKET
  • FIGURE 11. AQUACULTURE VACCINES MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. AQUACULTURE VACCINES MARKET FOR ATTENUATED LIVE VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. AQUACULTURE VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. AQUACULTURE VACCINES MARKET FOR SUBUNIT VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. AQUACULTURE VACCINES MARKET FOR DNA VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. AQUACULTURE VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. AQUACULTURE VACCINES MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 18. AQUACULTURE VACCINES MARKET FOR ORAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. AQUACULTURE VACCINES MARKET FOR INJECTED, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. AQUACULTURE VACCINES MARKET FOR IMMERSION AND SPRAY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. AQUACULTURE VACCINES MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 22. AQUACULTURE VACCINES MARKET FOR BACTERIAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. AQUACULTURE VACCINES MARKET FOR PARASITIC, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. AQUACULTURE VACCINES MARKET FOR VIRAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: AQUACULTURE VACCINES MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. ZOETIS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. ZOETIS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. ZOETIS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. HIPRA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. HIPRA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. HIPRA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. MERCK AND CO. INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. MERCK AND CO. INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. MERCK AND CO. INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. NISSEIKEN CO. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. NISSEIKEN CO. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. NISSEIKEN CO. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. ELANCO: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. ELANCO: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. ELANCO: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. PHIBRO ANIMAL HEALTH CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. PHIBRO ANIMAL HEALTH CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. PHIBRO ANIMAL HEALTH CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. KBNP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. KBNP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. KBNP: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. CAVAC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. CAVAC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. CAVAC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. KYOTO BIKEN LABORATORIES, INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. KYOTO BIKEN LABORATORIES, INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. KYOTO BIKEN LABORATORIES, INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. NISSEIKEN CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. NISSEIKEN CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. NISSEIKEN CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Aquaculture Vaccines Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue